Kanabo Group Plc
Business Update
4 April 2025
Kanabo Group plc ("Kanabo" or the "Company") (LSE: KNB), a leader in digital health services and specialised medicines (including medicinal cannabis) wishes to update the market regarding the Company's financial position and strategic direction.
On 4 March 2025, the Company announced that it continues to review its strategic direction and assess the need for additional resources to develop commercial AI technology. The Company's financial position has become more uncertain over the past month. The Company is engaged in ongoing discussions regarding a potential restructuring of its business, which may involve, among other options, asset disposals, mergers, or a refocus on the Company's core business lines. The Company is also continuing to assess its capital needs and funding requirements, including potential fundraising alternatives.
In light of the uncertainty regarding the Company's financial position, the Company anticipates that completion and publication of the Company's audited accounts for the year ended 31 December 2024 will be delayed.
Enquiries:
| Kanabo Group plc Avihu Tamir, Chief Executive Officer Odelia Vazana , Chief Financial Officer | +44 (0)20 7469 0930 |
| Peterhouse Capital Limited (Financial Adviser and Broker) Guy Miller / Lucy Williams / Charles Goodfellow | +44 (0)20 7469 0930 |
About Kanabo Group plc (LSE: KNB) Kanabo Group plc is a digital health company committed to improving patient care through its specialised technology platform and treatments, including medicinal cannabis.
Kanabo's NHS-approved telehealth platform, The GP Service, provides video consultations, online prescriptions, and comprehensive primary care. Treat It, the Company's specialised clinic, extends these services to chronic pain management and mental health indications, offering patients access to secondary care.
With two complementary business divisions, Kanabo delivers end-to-end digital health solutions, from telehealth consultations and prescriptions to tailored treatments. Its partially owned subsidiary, Kanabo Agritec Ltd, offers cultivation consultancy, enabling reliable access to high-quality raw materials for Kanabo's product range.
Kanabo Group plc remains focused on delivering high-quality medical solutions that make healthcare more accessible for patients across the UK and beyond.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.